Press release: NASC
The National Animal Supplement Council (NASC) has shared positive results from a recently completed study that has been submitted for peer review showing the tolerability of broad spectrum cannabidiol (CBD), broad spectrum CBD with cannabigerol (CBG) and broad-spectrum CBD with cannabidiolic acid (CBDA) in healthy male and female dogs when given a daily dose for 90 consecutive days.
Consumer trends are showing growth not only towards supplements for their own food and nutrition, but towards their pet’s overall health as well. Pet owners are increasingly turning to cannabidiol (CBD) products to help support and maintain their furry family members’ quality of life and these products have been shown to have a variety of benefits.
“Part of what makes this study unique is the data from support from the NASC’s Adverse Event Reporting System (NAERS™) which is the most advanced system of post market surveillance in the world,” said Bill Bookout, president of NASC. “Through this system, NASC members enter their products, ingredients, administration recommendations into the NAERS database along with the number of units in each container provided to customers. These collective data are processed by algorithms in the system and Adverse Events, both serious and non-serious can be compared and analyzed per million administrations.”
In the randomized, non-blinded, negative controlled, parallel design repeat dose study, healthy dogs (16 males and 16 females) at least 6-months of age were randomly placed into four groups and given either medium chain triglyceride oil as the control or one of the following: a broad spectrum cannabidiol, a broad spectrum cannabidiol with cannabigerol, or a broad spectrum cannabidiol with cannabidiolic acid at 5 mg total cannabinoids/kg body weight/day for 90 consecutive days. Animals were observed daily with detailed clinical examinations conducted weekly. Body weights, food consumption and clinical pathology evaluations were included in the study as well.
Nutrasource director of preclinical and companion animal services, Dr. Margitta Dziwenka, DVM, DABT comments, “This research is a game-changer for pet health offering an expanded horizon for veterinarians, industry, and pet owners alike. These findings grant us a renewed sense of confidence in exploring CBD product development for use in companion animals, so that industry can confidently answer the call and growing demand for natural and alternative products.”
Results showed that Cannabinoids were well tolerated when healthy male and female dogs were dosed for 90 consecutive days. Upon completion, all animals were reported to have no serious adverse events reported during the study. Post-market surveillance data for hemp-derived supplement products sold for use in dogs from 2010 to April 2023 shows that the rate per 1 million administrations sold is 2.19 and 0.01, for adverse events and serious adverse events, respectively. Based on the data available it was the conclusion of the authors that these substances do not pose significant risk to dogs in long-term use.o